2. Ankawi G, Fan W, Pomarè Montin D, et al. A new series of sorbent devices for multiple clinical purposes: current evidence and future directions.
Blood Purif 2019;47:94–100.
3. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability.
Kidney Int 2003;63:1934–1943.
5. Moradi H, Sica DA, Kalantar-Zadeh K. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease.
Am J Nephrol 2013;38:136–148.
6. Magnani S, Atti M. Uremic toxins and blood purification: a review of current evidence and future perspectives.
Toxins (Basel) 2021;13:246.
7. Gurland HJ, Davison AM, Bonomini V, et al. Definitions and terminology in biocompatibility.
Nephrol Dial Transplant 1994;9:4–10.
8. Yatzidis H. A convenient hemoperfusion microapparatus over charcoal for the treatment of endogenous and exogenous intoxification: Its use as an effective artificial kidney. Proc Eur Dial Transpl Assoc 1964;1:83–87.
10. Przepiórski J, Tryba B, Morawski AW. Adsorption of carbon dioxide on phenolic resin-based carbon spheres.
Appl Surf Sci 2002;196:296–300.
11. Miao J, Zhang F, Takieddin M, Mousa S, Linhardt RJ. Adsorption of doxorubicin on poly(methyl methacrylate)-chitosan-heparin-coated activated carbon beads.
Langmuir 2012;28:4396–4403.
12. Tang T, Li X, Xu Y, et al. Bilirubin adsorption on amine/methyl bifunctionalized SBA-15 with platelet morphology.
Colloids Surf B Biointerfaces 2011;84:571–578.
13. Murugavel S. In vitro studies of the efficacy of reversed phase silica gel as a sorbent for hemo- and plasmaperfusion.
J Toxicol Clin Toxicol 1992;30:69–82.
14. Zhang LX, Zhu M, Guo LM, Li L, Shi JL. Bilirubin adsorption property of mesoporous silica and amine-grafted mesoporous silica.
Nano-Micro Lett 2009;1:14–18.
15. Dou W, Wang J, Yao Z, Xiao W, Huang M, Zhang L. A critical review of hemoperfusion adsorbents: materials, functionalization and matrix structure selection.
Mater Adv 2022;3:918–930.
16. Clark WR, Ferrari F, La Manna G, Ronco C. Extracorporeal sorbent technologies: basic concepts and clinical application.
Contrib Nephrol 2017;190:43–57.
17. Pond SM. Extracorporeal techniques in the treatment of poisoned patients.
Med J Aust 1991;154:617–622.
18. Chang TM. Microcapsule artificial kidney: including updated preparative procedures and properties. Kidney Int Suppl 1976;(7):S218–S224.
19. Andrade JD, Kunitomo K, Van Wagenen R, Kastigir B, Gough D, Kolff WJ. Coated adsorbents for direct blood perfusion: HEMA-activated carbon.
Trans Am Soc Artif Intern Organs 1971;17:222–228.
20. Cai N, Li Q, Zhang J, et al. Antifouling zwitterionic hydrogel coating improves hemocompatibility of activated carbon hemoadsorbent.
J Colloid Interface Sci 2017;503:168–177.
21. Jiang S, Cao Z. Ultralow-fouling, functionalizable, and hydrolysable zwitterionic materials and their derivatives for biological applications.
Adv Mater 2010;22:920–932.
22. Mikhalovsky SV. Emerging technologies in extracorporeal treatment: focus on adsorption.
Perfusion 2003;18 Suppl 1:47–54.
23. Ingavle GC, Baillie LW, Zheng Y, et al. Affinity binding of antibodies to supermacroporous cryogel adsorbents with immobilized protein A for removal of anthrax toxin protective antigen.
Biomaterials 2015;50:140–153.
24. Terayama T, Yamakawa K, Umemura Y, Aihara M, Fujimi S. Polymyxin B hemoperfusion for sepsis and septic shock: a systematic review and meta-analysis.
Surg Infect (Larchmt) 2017;18:225–233.
25. Wu S, Duan B, Zeng X, et al. Construction of blood compatible lysine-immobilized chitin/carbon nanotube microspheres and potential applications for blood purified therapy.
J Mater Chem B 2017;5:2952–2963.
26. Yang Y, Yu YT, Song JC, et al. A new DNA immune adsorbent for hemoperfusion in SLE therapy: a clinical trial.
Artif Organs 1988;12:444–446.
27. Zheng H, Lang Y, Yu J, Han Z, Chen B, Wang Y. Affinity binding of aptamers to agarose with DNA tetrahedron for removal of hepatitis B virus surface antigen.
Colloids Surf B Biointerfaces 2019;178:80–86.
28. Zhao R, Li Y, Li X, et al. Facile hydrothermal synthesis of branched polyethylenimine grafted electrospun polyacrylonitrile fiber membrane as a highly efficient and reusable bilirubin adsorbent in hemoperfusion.
J Colloid Interface Sci 2018;514:675–685.
29. Qiao Y, Zhao J, Li P, et al. Adsorbents with high selectivity for uremic middle molecular peptides containing the Asp-Phe-Leu-Ala-Glu sequence.
Langmuir 2010;26:7181–7187.
30. Ronco C, Bordoni V, Levin NW. Adsorbents: from basic structure to clinical application.
Contrib Nephrol 2002;(137):158–164.
31. Clark WR, Gao D, Lorenzin A, Ronco C. Membranes and sorbents.
Contrib Nephrol 2018;194:70–79.
32. Li Z, Wang G, Zhen G, Zhang Y, Liu J, Liu S. Effects of hemodialysis combined with hemoperfusion on severe acute pancreatitis.
Turk J Gastroenterol 2018;29:198–202.
33. La Manna G, Donati G. Coupled plasma filtration adsorption: a multipurpose extracorporeal detoxification therapy.
Blood Purif 2018;46:228–238.
34. Redant S, De Bels D, Ismaili K, Honoré PM. Membrane-based therapeutic plasma exchange in intensive care.
Blood Purif 2021;50:290–297.
35. Wu M, Zhang H, Huang Y, Wu W, Huang J, Yan D. Efficiency of double plasma molecular absorption system on the acute severe cholestatic hepatitis.
Blood Purif 2021;50:876–882.
36. Rodeia SC, Martins FL, Fortuna P, Bento L. Cytokine adsorption therapy during extracorporeal membrane oxygenation in adult patients with COVID-19.
Blood Purif 2022;51:791–798.
37. Ghannoum M, Hoffman RS, Gosselin S, Nolin TD, Lavergne V, Roberts DM. Use of extracorporeal treatments in the management of poisonings.
Kidney Int 2018;94:682–688.
38. King JD, Kern MH, Jaar BG. Extracorporeal removal of poisons and toxins.
Clin J Am Soc Nephrol 2019;14:1408–1415.
39. Falkenhagen D, Gottschall S, Esther G, Courtney JM, Klinkmann H. In vitro assessment of charcoal and resin hemoadsorbents.
Contrib Nephrol 1982;29:23–33.
40. Rahman MH, Haqqie SS, McGoldrick MD. Acute hemolysis with acute renal failure in a patient with valproic acid poisoning treated with charcoal hemoperfusion.
Hemodial Int 2006;10:256–259.
41. Mydlík M, Derzsiová K, Bucek J, Horký K, Jarcuska J, Takác M. Use of charcoal haemoperfusion in 55 acute poisonings.
Life Support Syst 1983;1 Suppl 1:53–56.
42. Favin FD, Klein-Schwartz W, Oderda GM, Rose SR. In vitro study of lithium carbonate adsorption by activated charcoal.
J Toxicol Clin Toxicol 1988;26:443–450.
43. Roberts DM, Yates C, Megarbane B, et al. Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement.
Crit Care Med 2015;43:461–472.
44. Ghannoum M, Lavergne V, Gosselin S, et al. Practice trends in the use of extracorporeal treatments for poisoning in four countries.
Semin Dial 2016;29:71–80.
45. Hong SY, Yang JO, Lee EY, Kim SH. Effect of haemoperfusion on plasma paraquat concentration in vitro and in vivo.
Toxicol Ind Health 2003;19:17–23.
46. Rao R, Bhat R, Pathadka S, Chenji SK, Dsouza S. Golden hours in severe paraquat poisoning: the role of early haemoperfusion therapy.
J Clin Diagn Res 2017;11:OC06–OC08.
48. Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review.
Crit Care 2007;11:R47.
50. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.
JAMA 2009;301:2445–2452.
52. Dellinger RP, Bagshaw SM, Antonelli M, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial.
JAMA 2018;320:1455–1463.
53. Boss K, Jahn M, Wendt D, et al. Extracorporeal cytokine adsorption: significant reduction of catecholamine requirement in patients with AKI and septic shock after cardiac surgery.
PLoS One 2021;16:e0246299.
54. Paul R, Sathe P, Kumar S, Prasad S, Aleem M, Sakhalvalkar P. Multicentered prospective investigator initiated study to evaluate the clinical outcomes with extracorporeal cytokine adsorption device (CytoSorb) in patients with sepsis and septic shock.
World J Crit Care Med 2021;10:22–34.
56. Taniguchi T. Cytokine adsorbing columns.
Contrib Nephrol 2010;166:134–141.
57. Schädler D, Pausch C, Heise D, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial.
PLoS One 2017;12:e0187015.
58. Diab M, Lehmann T, Bothe W, et al. Cytokine hemoadsorption during cardiac surgery versus standard surgical care for infective endocarditis (REMOVE): results from a multicenter randomized controlled trial.
Circulation 2022;145:959–968.
59. Huang Z, Wang SR, Yang ZL, Liu JY. Effect on extrapulmonary sepsis-induced acute lung injury by hemoperfusion with neutral microporous resin column.
Ther Apher Dial 2013;17:454–461.
60. Huang Z, Wang SR, Su W, Liu JY. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column.
Ther Apher Dial 2010;14:596–602.
61. Sazonov V, Abylkassov R, Tobylbayeva Z, Saparov A, Mironova O, Poddighe D. Case series: efficacy and safety of hemoadsorption with HA-330 adsorber in septic pediatric patients with cancer.
Front Pediatr 2021;9:672260.
62. Chu L, Li G, Yu Y, Bao X, Wei H, Hu M. Clinical effects of hemoperfusion combined with pulse high-volume hemofiltration on septic shock.
Medicine (Baltimore) 2020;99:e19058.
63. Monard C, Rimmelé T, Ronco C. Extracorporeal blood purification therapies for sepsis.
Blood Purif 2019;47 Suppl 3:1–14.
65. Wei T, Chen Z, Li P, et al. Early use of endotoxin absorption by oXiris in abdominal septic shock: a case report.
Medicine (Baltimore) 2020;99:e19632.
66. Guan M, Wang H, Tang X, et al. Continuous renal replacement therapy with adsorbing filter oXiris in acute kidney injury with septic shock: a retrospective observational study.
Front Med (Lausanne) 2022;9:789623.
67. Zhang L, Yan Tang GK, Liu S, et al. Hemofilter with adsorptive capacities: case report series.
Blood Purif 2019;47 Suppl 3:1–6.
68. Fajgenbaum DC, June CH. Cytokine storm.
N Engl J Med 2020;383:2255–2273.
69. Ronco C, Bagshaw SM, Bellomo R, et al. Extracorporeal blood purification and organ support in the critically ill patient during COVID-19 pandemic: expert review and recommendation.
Blood Purif 2021;50:17–27.
70. Niazi NS, Nassar TI, Stewart IJ, Honore PM, Sharma K, Chung KK. A review of extracorporeal blood purification techniques for the treatment of critically ill coronavirus disease 2019 patients.
ASAIO J 2022;68:1219–1227.
71. Rizvi S, Danic M, Silver M, LaBond V. Cytosorb filter: an adjunct for survival in the COVID-19 patient in cytokine storm? A case report.
Heart Lung 2021;50:44–50.
72. Rampino T, Gregorini M, Perotti L, et al. Hemoperfusion with CytoSorb as adjuvant therapy in critically ill patients with SARS-CoV2 pneumonia.
Blood Purif 2021;50:566–571.
73. Hashemian SM, Shafigh N, Afzal G, et al. Blood purification techniques, inflammatory mediators and mortality in COVID-19 patients.
Tanaffos 2020;19:291–299.
74. Soleimani A, Taba SM, Hasibi Taheri S, Loghman AH, Shayestehpour M. The effect of hemoperfusion on the outcome, clinical and laboratory findings of patients with severe COVID-19: a retrospective study.
New Microbes New Infect 2021;44:100937.
75. Berlot G, Tomasini A, Roman Pognuz E, et al. The combined use of tocilizumab and hemoadsorption in a patient with SARS-COV-2-19-associated pneumonia: a case report.
Nephron 2020;144:459–462.
77. Alharthy A, Faqihi F, Memish ZA, et al. Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: a case-series.
Artif Organs 2021;45:E101–E112.
78. Stockmann H, Thelen P, Stroben F, et al. CytoSorb rescue for COVID-19 patients with vasoplegic shock and multiple organ failure: a prospective, open-label, randomized controlled pilot study.
Crit Care Med 2022;50:964–976.
80. Olson SW, Oliver JD, Collen J, et al. Treatment for severe coronavirus disease 2019 with the Seraph-100 Microbind Affinity Blood Filter.
Crit Care Explor 2020;2:e0180.
82. Schmidt JJ, Borchina DN, Van’t Klooster M, et al. Interim analysis of the COSA (COVID-19 patients treated with the Seraph 100 Microbind Affinity filter) registry.
Nephrol Dial Transplant 2022;37:673–680.
83. Padala SA, Vakiti A, White JJ, Mulloy L, Mohammed A. First reported use of highly adsorptive hemofilter in critically ill COVID-19 patients in the USA.
J Clin Med Res 2020;12:454–457.
87. Botella J, Ghezzi PM, Sanz-Moreno C. Adsorption in hemodialysis.
Kidney Int Suppl 2000;76:S60–S65.
88. Cheng W, Luo Y, Wang H, et al. Survival outcomes of hemoperfusion and hemodialysis versus hemodialysis in patients with end-stage renal disease: a systematic review and meta-analysis.
Blood Purif 2022;51:213–225.
89. Chen SJ, Jiang GR, Shan JP, et al. Combination of maintenance hemodialysis with hemoperfusion: a safe and effective model of artificial kidney.
Int J Artif Organs 2011;34:339–347.
90. Xiao Y. Effect of hemodialysis combined with blood perfusion on the treatment effect and long-term survival rate of patients with chronic renal failure and heart failure. J Med Ther Pract 2017;30:2725–2726.
91. Li X, Kong Y, Guanqing Xiao G, et al. Observation of medium and long term efficacy of hemodialysis combined with hemoperfusion on the endo-thelial function in patients with maintance hemodialysis. J Pract Med 2017;(24):3437–3440.
92. Zhong J, Huang Z, Li F. Effect of different dialysis methods on the outcome of patients with uremia complicated by heart failure and their effects on myocardial enzyme levels. J QDU Med 2018;054:407–409.
93. Wang Y, Wang Z, Ma S, Zhang H. Effect of hemoperfusion and hemodialysis on microinflammation and cardiovascular and cerebrovascular events in uremic patients. Chin J Heal C Med 2020;22:173–175.
94. Raine A, Cordonnier D, Ritz E. Effect of hematodialysis plus hemoperfusion on insulin resistance and nutritional status of patients with end-stage diabetic nephropathy. J Int Transl Med 2015;3:180–184.
95. Zhang J, Yuan Y, An X, et al. Comparison of combined blood purification techniques in treatment of dialysis patients with uraemic pruritus. Int J Clin Exp Med 2016;9:8563–8568.
96. Li WH, Yin YM, Chen H, et al. Curative effect of neutral macroporous resin hemoperfusion on treating hemodialysis patients with refractory uremic pruritus.
Medicine (Baltimore) 2017;96:e6160.
97. Long Q, Qin JP, Li R, Chang J, Jiang GR, Zhu C. Effects of hemodialysis and hemoperfusion combination treatment on maintenance hemodialysis patients. J Shanghai Jiaotong Univ (Med Sci) 2019;39:886–892.
99. Rocchetti MT, Cosola C, di Bari I, et al. Efficacy of divinylbenzenic resin in removing indoxyl sulfate and p-cresol sulfate in hemodialysis patients: results from an in vitro study and an in vivo pilot trial (xuanro4-Nature 3.2).
Toxins (Basel) 2020;12:170.
100. Gu YH, Yang XH, Pan LH, Zhan XL, Guo LL, Jin HM. Additional hemoperfusion is associated with improved overall survival and self-reported sleep disturbance in patients on hemodialysis.
Int J Artif Organs 2019;42:347–353.
101. Tang W, Sun X, Chen R, Zhao X. The observation effect of MHD combined with HP on improving the quality of life and prognosis of maintenance hemodialysis patients. Zhejiang Clin Med J 2014;12:1958–1959.
102. Yamaji K. Immunoadsorption for collagen and rheumatic diseases.
Transfus Apher Sci 2017;56:666–670.
103. Stummvoll G, Aringer M, Handisurya A, Derfler K. Immunoadsorption in autoimmune diseases affecting the kidney.
Semin Nephrol 2017;37:478–487.
104. Santos JM, Alolod MK. HA-130 hemoperfusion cartridge in the treatment of cast nephropathy in a 58-year-old male with multiple myeloma: a case report. Nephrol Dial Transplant 2020;35:iii1441.
105. Rosales A, Madrid A, Muñoz M, Dapena JL, Ariceta G. Charcoal hemoperfusion for methotrexate toxicity: a safe and effective life-rescue alternative when glucarpidase is not available.
Front Pediatr 2021;9:635152.